Please assess the completion status of the following clinical trial:

Trial Title: Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Diagnosis of Fanconi Anemia or other suspected DNA breakage/chromosomal instability syndromes, such as dyskeratosis congenita or Nijmegen breakage syndrome of all ages are eligible.~Diagnosis of Fanconi anemia confirmed by studies of peripheral blood or bone marrow sensitivity to mitomycin C or DEB or clinical evidence of other DNA breakage/chromosomal instability syndrome as determined by genetic testing or clinical diagnosis by a geneticist~Severe aplasia anemia as evidenced by a hypocellular bone marrow and at least 1 of the 3 criteria below: ANC \< 500/mm3 Hemoglobin \< 10 gm/dl with reticulocyte count \< 1% Platelet count \< 50,000/mm3~Availability of an HLA matched or mismatched (up to one haplotype) family member who has been documented not to have Fanconi anemia or of an unrelated HLA matched stem cell donor. Fully matched is defined at 6/6 match by high resolution DR based DNA typing.~Life expectancy greater than 6 weeks limited by diseases other than FA~Creatinine 2X normal for age or less~Karnofsky score 70% or more~Exclusion Criteria:~Patients with symptomatic cardiac disease, or evidence of significant cardiac disease by echocardiogram (i.e., shortening fraction less than 25%).~Patients with known allergy to rat serum products.~Patients with a severe infection that on evaluation by the Principal Investigator precludes ablative chemotherapy or successful transplantation.~Patients with severe personality disorder or mental illness.~Patients with documented HIV positivity.~Pregnant~NOTE: Patients who would be excluded from the protocol strictly for laboratory abnormalities can be included at the investigator's discretion after approval by the CCGT Protocol Review Committee and the FDA Reviewer.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm Study: Stem Cell Transplant (Type: EXPERIMENTAL): CAMPATH-1H Anti-CD45 Fludarabine Stem Cell Infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).